Study summary · research use only
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses hypoactive sexual desire disorder (HSDD) in women, covering physiology, assessment, diagnosis, and treatment strategies for clinicians. It states nearly half of women in the United States report problems with sexual function, and describes HSDD as a deficiency of sexual thoughts, feelings, or receptiveness to sexual stimulation present for at least 6 months, causing personal distress, and not attributable to another medical condition. The authors describe multiple hormones and neurotransmitters as likely participating in a dual-control model balancing excitation and inhibition of sexual desire, though a definitive physiology is not established. The review discusses validated screening tools and biopsychosocial assessment, and reviews the two medications approved for HSDD, flibanserin and bremelanotide, along with off-label treatments.
Abstract
Nearly half of women in the United States report problems with sexual function. Many health care providers do not ask about sexual concerns during routine clinical encounters because of personal discomfort, lack of familiarity with treatment, or the belief that they lack adequate time to address this complex issue. This may be especially true for hypoactive sexual desire disorder (HSDD), the most commonly identified sexual problem among women. HSDD is characterized by a deficiency of sexual thoughts, feelings, or receptiveness to sexual stimulation that has been present for at least 6 months, causes personal distress, and is not due to another medical condition. This is an up-to-date overview of HSDD for clinicians, discussing its physiology, assessment, diagnosis, and treatment strategies. Although a definitive physiology of HSDD is still unknown, multiple hormones and neurotransmitters likely participate in a dual-control model to balance excitation and inhibition of sexual desire. For assessment and diagnosis, validated screening tools are discussed, and the importance of a biopsychosocial assessment is emphasized, with guidance on how this can be implemented in clinical encounters. The 2 recently approved medications for HSDD, flibanserin and bremelanotide, are reviewed as well as off-label treatments. Overall, HSDD represents a common yet likely underrecognized disorder that midwives and other health care providers who care for women across the life span are in a unique position to address.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.